Iris Kanera

4 91 Use and appreciation of the Kanker Nazorg Wijzer Table 4.2 Overall baseline characteristics of the KNW participants and categorized for module-use ( N = 231) Modules of the Kanker NazorgWijzer Overall No module Fatigue Return to work Mood Relation ships Physical Activity Diet Smoking Residual Symptoms N = 231 n = 33 14.3% n = 82 35.5% n = 53 22.9% n = 49 21.2% n = 38 16.5% n = 51 22.1% n = 134 58% n = 23 10% n = 47 20.4% Female, n (%) 183 (79.2) 26 (78.8) 63 (76.8) 46 (86.8) 41 (83.7) 30 (79.0) 44 (86.3) 106 (79.1) 17 (73.9) 40 (85.1) Age, M ( SD ) 55.6 (11.5) 52.5 (10.7) 55.1 (11.6) 52.8 (9.5) 54.4 (11.7) 55.9 (12.1) 56.3 (9.7) 56.0 (11.1) 51.6 (8.7) 56.2 (9.0) With partner, n (%) 193 (83.6) 27 (81.8) 65 (79.3) 43 (81.1) 37 (75.5) 31 (81.6) 42 (82.4) 109 (81.3) 16 (69.6) 36 (76.6) BMI, M ( SD ) 26.0 (5.0) 27.2 (7.3) 26.2 (4.3) 25.7 (5.0) 25.3 (4.0) 26.1 (3.5) 26.1 (3.6) 25.4 (4.7) 24.8 (3.1) 25.4 (3.9) Education, n (%) Low 76 (32.9) 13 (39.4) 23 (28.1) 12 (22.6) 15 (30.6) 12 (31.6) 18 (35.3) 42 (31.3) 9 (39.1) 13 (27.7) Medium 76 (32.9) 12 (36.4) 31 (37.8) 20 (37.7) 20 (40.8) 13 (34.2) 18 (35.3) 44 (32.8) 7 (30.4) 14 (29.8) High 79 (34.2) 8 (24.2) 28 (34.2) 21 (39.6) 14 (28.6) 13 (34.2) 15 (29.4) 48 (35.8) 7 (30.4) 20 (42.6) Working at baseline, n (%) 122 (52.8) 20 (60.6) 40 (48.8) 38 (71.7) 28 (57.1) 18 (47.4) 27 (52.9) 70 (52.2) 13 (56.5) 26 (55.3) Type of cancer, n (%) Breast 162 (70.1) 24 (72.7) 55 (67.1) 40 (75.5) 36 (73.5) 27 (71.1) 41 (80.4) 94 (70.2) 18 (78.3) 32 (68.1) Colon 29 (12.6) 4 (12.1) 10 (12.2) 4 (7.6) 6 (12.2) 5 (13.2) 2 (3.9) 19 (14.2) 3 (13.0) 9 (19.2) Other 40 (17.3) 5 (15.2) 17 (20.7) 9 (16.9) 7 (14.3) 6 (15.8) 8 (15.7) 21 (15.7) 2 (8.7) 6 (12.8) Had cancer before, n (%) 24 (10.4) 5 (15.2) 8 (9.8) 3 (5.7) 4 (8.2) 3 (7.9) 5 (9.8) 13 (9.7) 2 (8.7) 5 (10.6) Treatment, n (%) Surgery, chemo, radio 86 (37.2) 11 (33.3) 37 (45.1) 20 (37.7) 20 (40.8) 18 (47.4) 22 (43.1) 53 (39.6) 11 (47.8) 22 (46.8) Surgery, chemo 61 (26.4) 11 (33.3) 17 (20.7) 16 (30.2) 16 (32.7) 9 (23.7) 12 (23.5) 35 (26.1) 7 (30.4) 15 (31.9) Surgery, radio 46 (19.9) 5 (15.2) 15 (18.3) 11 (20.8) 10 (20.4) 5 (13.2) 11 (21.6) 26 (19.4) 3 (13.0) 8 (17.1) other 38 (16.5) 6 (18.2) 13 (15.9) 6 (11.3) 3 (6.1) 6 (15.8) 6 (11.8) 20 (14.9) 2 (8.7) 2 (4.3) Weeks since completion treatment, M ( SD ) 25.1 (13.5) 27.1 (15.6) 24.1 (14.4) 22.3 (13.7) 25.3 (13.6) 26.5 (12.9) 23.7 (13.6) 25.0 (13.1) 22.1 (13.2) 25.4 (3.9) Having comorbidities, n (%) 62 (26.8) 10 (30.3) 25 (30.5) 14 (26.4) 12 (24.5) 10 (26.3) 15 (29.4) 34 (25.4) 7 (30.4) 8 (17.0) Using aftercare, n (%) 145 (62.8) 25 (75.8) 46 (56.1) 38 (71.7) 32 (65.3) 29 (76.3) 31 (60.8) 83 (61.9) 12 (52.2) 29 (61.7)